secwatch.observer — SEC 8-K summary
======================================

Issuer:     NovoCure Ltd (NVCR)
CIK:        0001645113
Form:       8-K
Filed at:   2026-06-30T11:00:24+00:00
Accession:  0001645113-26-000056
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Novocure's Optune Pax receives CE Mark for locally advanced pancreatic cancer
-----------------------------------------------------------------------------

- CE Mark supported by Phase 3 PANOVA-3 trial showing statistically significant mOS improvement.
- mOS 16.2 vs 14.2 months (HR 0.82, p=0.039) in ITT; 18.3 vs 15.1 months in mITT.
- Time to pain progression extended 6.1 months (15.2 vs 9.1 months, HR 0.74, p=0.027).
- Optune Pax already FDA-approved Feb 2026; launch in Germany planned in coming weeks.
- Device well-tolerated; most AEs mild-moderate skin events; no new safety signals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645113/000164511326000056/0001645113-26-000056-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645113/000164511326000056/nvcr-20260630.htm
  HTML page:      https://secwatch.observer/filing/0001645113-26-000056

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer